CR10369A - Pyrimidine derivatives as pi3k inhibitors - Google Patents

Pyrimidine derivatives as pi3k inhibitors

Info

Publication number
CR10369A
CR10369A CR10369A CR10369A CR10369A CR 10369 A CR10369 A CR 10369A CR 10369 A CR10369 A CR 10369A CR 10369 A CR10369 A CR 10369A CR 10369 A CR10369 A CR 10369A
Authority
CR
Costa Rica
Prior art keywords
pyrimidine derivatives
pi3k inhibitors
pi3k
inhibitors
pyrimidine
Prior art date
Application number
CR10369A
Other languages
English (en)
Inventor
Stewart James Baker
Paul John Goldsmith
Timothy Colin Hancox
Neil Anthony Pegg
Stephen Price
Stephen Joseph Shuttleworth
Sukhjit Sohal
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0608264A external-priority patent/GB0608264D0/en
Priority claimed from GB0608397A external-priority patent/GB0608397D0/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR10369A publication Critical patent/CR10369A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
CR10369A 2006-04-26 2008-10-15 Pyrimidine derivatives as pi3k inhibitors CR10369A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0608264A GB0608264D0 (en) 2006-04-26 2006-04-26 Pharmaceutical compounds
GB0608397A GB0608397D0 (en) 2006-04-27 2006-04-27 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
CR10369A true CR10369A (es) 2009-01-09

Family

ID=38110021

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10369A CR10369A (es) 2006-04-26 2008-10-15 Pyrimidine derivatives as pi3k inhibitors

Country Status (15)

Country Link
US (2) US8252792B2 (es)
EP (1) EP2032582A1 (es)
JP (1) JP5302186B2 (es)
KR (1) KR20090021155A (es)
AU (1) AU2007242594A1 (es)
BR (1) BRPI0710866A2 (es)
CA (1) CA2650196A1 (es)
CR (1) CR10369A (es)
EC (1) ECSP088867A (es)
IL (1) IL194755A0 (es)
MA (1) MA30360B1 (es)
MX (1) MX2008013582A (es)
NO (1) NO20084832L (es)
RU (1) RU2008141356A (es)
WO (1) WO2007122410A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2041139E (pt) * 2006-04-26 2012-01-13 Hoffmann La Roche Compostos farmacêuticos
KR101460816B1 (ko) 2006-12-07 2014-11-12 에프. 호프만-라 로슈 아게 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
AU2007333243B2 (en) 2006-12-07 2013-03-14 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
EP2158207B1 (en) 2007-06-12 2011-05-25 F. Hoffmann-La Roche AG Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
MX338504B (es) 2007-09-12 2016-04-20 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
EP2207781B1 (en) 2007-09-24 2012-11-28 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
JP2011529920A (ja) 2008-07-31 2011-12-15 ジェネンテック， インコーポレイテッド ピリミジン化合物、組成物及び使用方法
US8778927B2 (en) 2008-10-01 2014-07-15 Novartis Ag Smoothened antagonism for the treatment of hedgehog pathway-related disorders
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
HUE027615T2 (en) 2009-01-08 2016-10-28 Curis Inc Phosphoinositide 3-kinase inhibitors containing zinc-binding radicals
US8158625B2 (en) 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
MX2011012520A (es) 2009-05-27 2011-12-12 Hoffmann La Roche Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
GEP20156325B (en) * 2009-06-17 2015-07-10 Vertex Pharma Inhibitors of influenza viruses replication
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
CA2771594C (en) * 2009-08-20 2018-05-01 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
RU2607635C2 (ru) 2009-11-12 2017-01-10 Ф.Хоффманн-Ля Рош Аг N-9-замещенные пуриновые соединения, композиции и способы применения
RU2515541C2 (ru) 2009-11-12 2014-05-10 Ф.Хоффманн-Ля Рош Аг N-7 замещенные пурины и пиразолопиримидины, их композиции и способы применения
CN105859735B (zh) 2010-12-16 2018-03-09 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
WO2013174794A1 (en) 2012-05-23 2013-11-28 F. Hoffmann-La Roche Ag Compositions and methods of obtaining and using endoderm and hepatocyte cells
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
US9676765B2 (en) 2012-11-07 2017-06-13 Karus Therapeutics Limited Histone deacetylase inhibitors and their use in therapy
RS57816B1 (sr) 2013-05-10 2018-12-31 Karus Therapeutics Ltd Inhibitori histon deacetilaze
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
JP6618901B2 (ja) 2013-11-13 2019-12-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
PL3068776T3 (pl) 2013-11-13 2019-10-31 Vertex Pharma Inhibitory replikacji wirusów grypy
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
LT3230289T (lt) 2014-12-11 2019-10-10 Natco Pharma Limited 7-(morfolinil)-2-(n-piperazinil)metiltieno[2, 3-c]piridino dariniai kaip priešvėžiniai vaistai
WO2016147543A1 (en) 2015-03-13 2016-09-22 Ricoh Company, Ltd. Electrochromic compound, electrochromic composition, electrochromic element, and electrochromic dimming element
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
WO2017201076A1 (en) * 2016-05-16 2017-11-23 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
AU2022260846A1 (en) * 2021-04-21 2023-11-16 Natco Pharma Limited Improved process for the preparation of 7-(morpholinyl)-2-(n-piperazinyl)methylthieno[2, 3-c]pyridine derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423716B1 (en) 1998-03-31 2002-07-23 Kyowa Hakko Kogyo Co., Ltd. Nitrogenous heterocyclic compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP3649395B2 (ja) 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
PT2041139E (pt) 2006-04-26 2012-01-13 Hoffmann La Roche Compostos farmacêuticos

Also Published As

Publication number Publication date
NO20084832L (no) 2008-11-18
EP2032582A1 (en) 2009-03-11
IL194755A0 (en) 2009-08-03
MA30360B1 (fr) 2009-04-01
US8252792B2 (en) 2012-08-28
US8697693B2 (en) 2014-04-15
CA2650196A1 (en) 2007-11-01
ECSP088867A (es) 2008-12-30
BRPI0710866A2 (pt) 2012-08-14
JP5302186B2 (ja) 2013-10-02
AU2007242594A1 (en) 2007-11-01
JP2009534453A (ja) 2009-09-24
US20100016306A1 (en) 2010-01-21
MX2008013582A (es) 2009-01-19
US20120283257A1 (en) 2012-11-08
WO2007122410A1 (en) 2007-11-01
KR20090021155A (ko) 2009-02-27
RU2008141356A (ru) 2010-06-10

Similar Documents

Publication Publication Date Title
CR10369A (es) Pyrimidine derivatives as pi3k inhibitors
CY2019027I1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
SMAP200800048A (it) Derivati pirimidinici utilizzati come inibitori dip13-chinasi
ATE506358T1 (de) 2-benzylpyridazinonderivate als met-kinasehemmer
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
BRPI0716477A2 (pt) Derivados heteroarila como inibidores de quinase protéica
ATE483711T1 (de) Spiroindolinonderivate
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
PL2044056T3 (pl) Pochodne pirymidyny jako inhibitory ALK-5
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2035394T3 (da) 2-pyrazincarboxamidderivater
CR10478A (es) Amino-piperidine derivatives as cetp inhibitors
BRPI0716781A2 (pt) Inibidores da quinase
ATE467623T1 (de) Diazepan-acetamidderivate als selektive 11-hsd1- hemmer
ES2465673T9 (es) Derivados de pirimidina
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
CR10879A (es) Cyclized derivatives as eg-5 inhibitors
ATE545417T1 (de) Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
DK2046802T3 (da) 2-substituerede methylpenamderivater
BRPI0720547A2 (pt) Inibidores de metaloprotease derivada de heterocíclico
DK2086968T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)